Ascendis Pharma A/S ADR (NASDAQ: ASND) on Friday, soared 4.75% from the previous trading day, before settling in for the closing price of $113.81. Within the past 52 weeks, ASND’s price has moved between $85.29 and $161.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 182.00% over the past five years. The company achieved an average annual earnings per share of 19.91%. With a float of $56.61 million, this company’s outstanding shares have now reached $56.61 million.
In terms of profitability, gross margin is 84.92%, operating margin of -111.42%, and the pretax margin is -149.63%.
Ascendis Pharma A/S ADR (ASND) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ascendis Pharma A/S ADR is 1.30%, while institutional ownership is 105.61%.
Ascendis Pharma A/S ADR (ASND) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 19.91% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.02% during the next five years compared to -19.87% drop over the previous five years of trading.
Ascendis Pharma A/S ADR (NASDAQ: ASND) Trading Performance Indicators
Ascendis Pharma A/S ADR (ASND) is currently performing well based on its current performance indicators. A quick ratio of 0.44 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -9.34, a number that is poised to hit -1.42 in the next quarter and is forecasted to reach -3.51 in one year’s time.
Technical Analysis of Ascendis Pharma A/S ADR (ASND)
Ascendis Pharma A/S ADR (NASDAQ: ASND) saw its 5-day average volume 1.08 million, a positive change from its year-to-date volume of 0.41 million. As of the previous 9 days, the stock’s Stochastic %D was 14.87%. Additionally, its Average True Range was 5.65.
During the past 100 days, Ascendis Pharma A/S ADR’s (ASND) raw stochastic average was set at 22.36%, which indicates a significant decrease from 26.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.20% in the past 14 days, which was higher than the 39.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $132.39, while its 200-day Moving Average is $134.62. Nevertheless, the first resistance level for the watch stands at $120.96 in the near term. At $122.71, the stock is likely to face the second major resistance level. The third major resistance level sits at $125.93. If the price goes on to break the first support level at $116.00, it is likely to go to the next support level at $112.78. Assuming the price breaks the second support level, the third support level stands at $111.04.
Ascendis Pharma A/S ADR (NASDAQ: ASND) Key Stats
Market capitalization of the company is 6.84 billion based on 58,231K outstanding shares. Right now, sales total 288,670 K and income totals -521,070 K. The company made 38,770 K in profit during its latest quarter, and -117,790 K in sales during its previous quarter.
